Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo tackles aggressive lymphoma that Won't quit

NCT ID NCT03321643

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 02, 2026 · Updated 29 times

Summary

This early-stage study tests a combination of four drugs (atezolizumab, gemcitabine, oxaliplatin, and rituximab) in about 24 people with a type of lymphoma that has come back or stopped responding to treatment. The main goals are to find the safest dose and see how well the drugs work together. This is not a cure, but aims to control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • City of Hope Comprehensive Cancer Center

    Duarte, California, 91010, United States

  • Emory University Hospital/Winship Cancer Institute

    Atlanta, Georgia, 30322, United States

  • UC San Diego Moores Cancer Center

    La Jolla, California, 92093, United States

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California, 95817, United States

Conditions

Explore the condition pages connected to this study.

RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA RECURRENT TRANSFORMED NON-HODGKIN LYMPHOMA REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY TRANSFORMED NON-HODGKIN LYMPHOMA RICHTER SYNDROME TRANSFORMED FOLLICULAR LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA